Physician profile
Paul D Natterson
NPI 1467458018
$4,264.05
in general payments reported to CMS, 2019-2025
37 companies · $985 in 2025
The $985 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $162 · 2021: $45.71 · 2022: $160 · 2023: $522 · 2024: $1,009 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $667.32 | 2019-2025 | |
| Amgen INC. | $565.38 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $279.50 | 2019-2024 | Xarelto |
| Pfizer INC. | $277.70 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $263.13 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.36 | 2019-2025 | Jardiance |
| Akcea Therapeutics, INC. | $218.87 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $184.14 | 2019-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $168.13 | 2019-2024 | Evkeeza, Praluent |
| E.R. Squibb & Sons, L.L.C. | $158.99 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $156.29 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $149.24 | 2019-2025 | Wainua, Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $95.58 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.82 | 2021-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $68.70 | 2023-2024 | Inpefa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Natterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.